Trends in Medically Integrated Dispensing Among Oncology Practices.
Journal
JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
pubmed:
14
7
2022
medline:
14
10
2022
entrez:
13
7
2022
Statut:
ppublish
Résumé
The integration of pharmacies with oncology practices-known as medically integrated dispensing or in-office dispensing-could improve care coordination but may incentivize overprescribing or inappropriate prescribing. Because little is known about this emerging phenomenon, we analyzed historical trends in medically integrated dispensing. Annual IQVIA data on oncologists were linked to 2010-2019 National Council for Prescription Drug Programs pharmacy data; data on commercially insured patients diagnosed with any of six common cancer types; and summary data on providers' Medicare billing. We calculated the national prevalence of medically integrated dispensing among community and hospital-based oncologists. We also analyzed the characteristics of the oncologists and patients affected by this care model. Between 2010 and 2019, the percentage of oncologists in practices with medically integrated dispensing increased from 12.8% to 32.1%. The share of community oncologists in dispensing practices increased from 7.6% to 28.3%, whereas the share of hospital-based oncologists in dispensing practices increased from 18.3% to 33.4%. Rates of medically integrated dispensing varied considerably across states. Oncologists who dispensed had higher patient volumes ( Medically integrated dispensing has increased significantly among oncology practices over the past 10 years. The reach, clinical impact, and economic implications of medically integrated dispensing should be evaluated on an ongoing basis.
Identifiants
pubmed: 35830621
doi: 10.1200/OP.22.00136
pmc: PMC9835967
doi:
Substances chimiques
Prescription Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1672-e1682Références
JAMA Oncol. 2019 Jun 01;5(6):893-899
pubmed: 30605222
Med Care. 1994 Feb;32(2):164-74
pubmed: 8302108
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Health Aff (Millwood). 2006 Mar-Apr;25(2):437-43
pubmed: 16522584
Health Aff (Millwood). 2014 May;33(5):756-63
pubmed: 24799571
J Gen Intern Med. 2010 Oct;25(10):1057-63
pubmed: 20532656
JAMA Intern Med. 2014 Jun;174(6):861-9
pubmed: 24710808
BMC Health Serv Res. 2008 Jan 14;8:12
pubmed: 18194561
Health Aff (Millwood). 2018 Jul;37(7):1123-1127
pubmed: 29985694
Pharmacotherapy. 2014 Oct;34(10):1012-21
pubmed: 25053590
JAMA Netw Open. 2021 May 3;4(5):e218055
pubmed: 33970260
Med Care Res Rev. 2022 Apr;79(2):317-327
pubmed: 34027744
Med Care Res Rev. 2018 Aug;75(4):399-433
pubmed: 29148355
J Clin Oncol. 2020 Feb 20;38(6):633-644
pubmed: 31815576
Health Aff (Millwood). 2010 Dec;29(12):2252-9
pubmed: 21134927
Med Care. 2008 May;46(5):460-6
pubmed: 18438193